DISREGARD RELEASE: Alphamab Oncology

November 13, 2024 | 18:29
(0) user say
We are advised by Alphamab Oncology that journalists and other readers should disregard the news release.

We are advised by Alphamab Oncology that journalists and other readers should disregard the news release, A Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Included in the Pilot Program for Optimizing the Review and Approval of Clinical Trials for Innovative Drugs, issued 13-Nov-2024 over PR Newswire.

By PR Newswire

Alphamab Oncology

What the stars mean:

★ Poor ★ ★ Promising ★★★ Good ★★★★ Very good ★★★★★ Exceptional